- Home
- MKTX vs CDTX Comparison
MKTX vs CDTX Comparison
Compare MKTX & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKTX | CDTX |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.0B |
| IPO Year | 2004 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MKTX | CDTX |
|---|---|---|
| Price | $171.51 | $221.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $210.27 | $128.75 |
| AVG Volume (30 Days) | 724.1K | ★ 1.0M |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.87 | N/A |
| Revenue | ★ $839,263,000.00 | N/A |
| Revenue This Year | $6.33 | N/A |
| Revenue Next Year | $8.10 | N/A |
| P/E Ratio | $29.58 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $156.17 | $15.22 |
| 52 Week High | $232.84 | $221.42 |
Technical Indicators
Market Signals| Indicator | MKTX | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 84.92 |
| Support Level | $177.31 | $220.47 |
| Resistance Level | $183.15 | $221.42 |
| Average True Range (ATR) | 3.00 | 0.41 |
| MACD | -1.39 | -2.93 |
| Stochastic Oscillator | 9.24 | 97.68 |
Price Performance
Historical ComparisonAbout MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.